Department of Research & Development, Amsterdam Molecular Therapeutics, Amsterdam, The Netherlands.
Hepatology. 2012 Mar;55(3):821-32. doi: 10.1002/hep.24682. Epub 2012 Jan 13.
Adenosine triphosphate (ATP)-binding cassette (ABC) transporters are drug efflux pumps responsible for the multidrug resistance phenotype causing hepatocellular carcinoma (HCC) treatment failure. Here we studied the expression of 15 ABC transporters relevant for multidrug resistance in 19 paired HCC patient samples (16 untreated, 3 treated by chemotherapeutics). Twelve ABC transporters showed up-regulation in HCC compared with adjacent healthy liver. These include ABCA2, ABCB1, ABCB6, ABCC1, ABCC2, ABCC3, ABCC4, ABCC5, ABCC10, ABCC11, ABCC12, and ABCE1. The expression profile and function of some of these transporters have not been associated with HCC thus far. Because cellular microRNAs (miRNAs) are involved in posttranscriptional gene silencing, we hypothesized that regulation of ABC expression in HCC might be mediated by miRNAs. To study this, miRNAs were profiled and dysregulation of 90 miRNAs was shown in HCC compared with healthy liver, including up-regulation of 11 and down-regulation of 79. miRNA target sites in ABC genes were bioinformatically predicted and experimentally verified in vitro using luciferase reporter assays. In total, 13 cellular miRNAs were confirmed that target ABCA1, ABCC1, ABCC5, ABCC10, and ABCE1 genes and mediate changes in gene expression. Correlation analysis between ABC and miRNA expression in individual patients revealed an inverse relationship, providing an indication for miRNA regulation of ABC genes in HCC.
Up-regulation of ABC transporters in HCC occurs prior to chemotherapeutic treatment and is associated with miRNA down-regulation. Up-regulation of five ABC genes appears to be mediated by 13 cellular miRNAs in HCC patient samples. miRNA-based gene therapy may be a novel and promising way to affect the ABC profile and overcome clinical multidrug resistance.
三磷酸腺苷(ATP)结合盒(ABC)转运蛋白是负责多药耐药表型的药物外排泵,导致肝细胞癌(HCC)治疗失败。在这里,我们研究了 19 对 HCC 患者样本(16 例未经治疗,3 例经化疗治疗)中 15 种与多药耐药相关的 ABC 转运蛋白的表达。与相邻健康肝脏相比,12 种 ABC 转运蛋白在 HCC 中上调。这些包括 ABCA2、ABCB1、ABCB6、ABCC1、ABCC2、ABCC3、ABCC4、ABCC5、ABCC10、ABCC11、ABCC12 和 ABCE1。迄今为止,这些转运蛋白中的一些的表达谱和功能与 HCC 无关。由于细胞 microRNAs(miRNAs)参与转录后基因沉默,我们假设 HCC 中 ABC 表达的调节可能由 miRNAs 介导。为了研究这一点,对 miRNAs 进行了分析,结果显示 HCC 与健康肝脏相比,miRNA 失调 90 个,包括上调 11 个和下调 79 个。ABC 基因的 miRNA 靶位点通过生物信息学预测,并在体外使用荧光素酶报告基因测定进行了实验验证。总共证实了 13 种细胞 miRNA 可以靶向 ABCA1、ABCC1、ABCC5、ABCC10 和 ABCE1 基因,并介导基因表达的变化。对个体患者中 ABC 和 miRNA 表达的相关分析显示出负相关,这表明 miRNA 对 HCC 中 ABC 基因的调节。
HCC 中 ABC 转运蛋白的上调发生在化疗治疗之前,并与 miRNA 下调相关。在 HCC 患者样本中,五个 ABC 基因的上调似乎是由 13 种细胞 miRNA 介导的。基于 miRNA 的基因治疗可能是一种新颖且有前途的方法,可以影响 ABC 谱并克服临床多药耐药性。